Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

According to Anand Kannappan, CEO and co-founder of Patronus AI, for agents to perform tasks at human-comparable levels, they ...

There's a vast world of PC games that let you tackle the mundane in creative and surprisingly enjoyable ways. Build a PC, run a pizza shop, or become a bee with these strange and wondrous titles. In ...